Table 3 Increase in Norepinephrine (NE) with Peripheral Alpha-1 Antagonists
From: A Review of the Adverse Effects of Peripheral Alpha-1 Antagonists in Hypertension Therapy
Study population | Reference | Study design | Drug | N | Findings | |
|---|---|---|---|---|---|---|
Normotensive | Takata [35] | observational | doxazosin | 8 | Trend towards increase in NE with therapy; 60% decrease in NE after withdrawal of therapy | |
Hypertensive | Izzo [36] | comparative | prazosin | 8 | 50% increase in NE; 0.9 kg wt gain | |
captopril | 8 | 12% decrease in NE, 0.82 kg wt loss, p < 0.01 for comparison | ||||
CHF | Colucci [37] | observational | prazosin | 10 | Increase in NE from 145 ± 133* to 481 ± 376 with therapy | |
Stein [38] | observational | prazosin | 8 | Increase in NE from 276 ± 347 to 521 ± 130 with therapy | ||
Markham [39] | RCT | prazosin | 25 | Treatment group NE increased from 790 ± 280 to 1413 ± 1030 after four weeks of therapy; placebo group was 749 ± 315 at baseline and 772 ± 596 at four weeks, p for difference at four weeks = 0.08. |